Putting the STING into cancer immunotherapy
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice.
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice.
With the new method, scientists can explore many cancer mutations whose roles are unknown, helping them develop new drugs that target those mutations.
The new diagnostic, which is based on analysis of urine samples, could also be designed to reveal whether a tumor has metastasized.
In a new study, immunostimulatory drugs slowed tumor growth without producing systemic inflammation.
If reactors are retired, polluting energy sources that fill the gap could cause more than 5,000 premature deaths, researchers estimate.
Researchers develop new, patient-friendly hydrogel platform for administering lifesaving biologics.
Using this approach, researchers hope to deliver therapeutic RNA molecules selectively to cancer cells or other target cells.
Immunology research, public health service, and student leadership are all part of senior Julian Zulueta’s journey toward becoming a physician-scientist.
A new study reveals that lymph nodes near the lungs create an environment that weakens T-cell responses to tumors.
Using bottlebrush-shaped particles, researchers can identify and deliver synergistic combinations of cancer drugs.
Deep-learning model takes a personalized approach to assessing each patient’s risk of lung cancer based on CT scans.
The late MIT Professor Angelika Amon was recognized as Committed to Caring for her generous and encompassing mentorship.
Biologists have mapped out more than 300 protein kinases and their targets, which they hope could yield new leads for cancer drugs.
Groundbreaking research can help alleviate the challenges affiliated with studying carbohydrates.
Koch Institute event celebrates the new MIT Press biography “Salvador Luria: An Immigrant Biologist in Cold War America.”